Events

Clean Energy Transition Partnership Annual Conference 2024
OCT
Tue
22
OCT
Wed
23

This was 1 year ago

Location

online

Programmes
Climate, Energy, Mobility

The CETPartnership Annual Conference 2024 brings together stakeholders in the clean energy transition for two days on 22 – 23 October. During several sessions, participants get the chance to contribute to policy discussions, learn more about how CETPartnership contributes to achieving the clean energy transition goals and engage in networking with several stakeholders.

What can you expect from the event?
  • Follow latest policy discussions and research results on burning topics of the clean energy transition.
  • Get new insights from experts on the role of research and innovation in addressing the clean energy transition.
  • Discover the key thematic challenges addressed by CETPartnership
  • Get to know CETPartnership funded projects and their endeavours
  • Learn about how the CETPartnership leverages research results in their Knowledge Community and Impact Network activities
  • Clarify all open questions and find potential project partners for the CETPartnership Joint Call 2024

Agenda and registration.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.